Advertisement
Screener

Aclaris Therapeutics, Inc. (ACRS) Graph

ACRS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $1.63M; Cost of revenue $218.00K; Research and development $18.07M; Operating expenses (m).
  • 2026-03-31: Revenue $2.00M; Cost of revenue $395.00K; Research and development $15.66M; Operating expenses (m).
  • 2025-12-31: Revenue $1.29M*; Cost of revenue $532.00K*; Research and development $16.58M*; Operating expenses (m).
  • 2025-09-30: Revenue $3.30M; Cost of revenue $538.00K; Research and development $13.03M; Operating expenses (m).

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ACRS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.License And Service$1.27MLaboratoryResearch Revenue$356.00KRevenue$1.63MCost of revenue$218.00KOperating income-$24.24MResearch & development$18.07MNet income-$21.50M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ACRS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Single ReportableSegment$1.63MRevenue$1.63MCost of revenue$218.00KOperating income-$24.24MResearch & development$18.07MNet income-$21.50M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30$1.63M$218.00K$18.07M(m)-$21.50M
2026-03-31$2.00M$395.00K$15.66M(m)-$19.82M
2025-12-31$1.29M*$532.00K*$16.58M*(m)-$19.80M*
2025-09-30$3.30M$538.00K$13.03M(m)-$14.61M
2025-06-30$1.78M$515.00K$11.45M(m)-$15.43M
2025-03-31$1.46M$506.00K$11.58M(m)-$15.09M
2024-09-30$4.35M$654.00K$5.96M(m)-$7.59M
2024-06-30$2.77M$624.00K$8.76M(m)-$10.99M
2024-03-31$2.40M$809.00K$9.85M(m)-$16.94M
2023-09-30$9.28M$848.00K$23.88M(m)-$29.26M
2023-06-30$1.87M$1.04M$25.27M(m)-$29.57M
2023-03-31$2.53M$808.00K$22.59M(m)-$28.16M
2022-09-30$19.02M$923.00K$23.66M(m)-$19.95M
2022-06-30$1.53M$1.07M$18.78M(m)-$20.53M
2022-03-31$1.45M$1.16M$14.31M(m)-$18.79M
2021-09-30$1.66M$1.10M$13.98M(m)-$21.15M
2021-06-30$1.82M$1.26M$7.90M(m)-$18.16M
2021-03-31$1.78M$1.20M$7.84M(m)-$28.75M
2020-09-30$1.45M$1.19M$6.24M(m)-$10.66M
2020-06-30$2.05M$1.39M$6.47M(m)-$11.60M
2020-03-31$1.41M$1.27M$7.68M(m)-$15.59M
2019-09-30$983.00K$826.00K$16.18M(m)-$55.32M
2019-06-30$886.00K$994.00K$17.52M(m)-$49.88M
2019-03-31$1.26M$1.21M$19.64M(m)-$37.56M
2018-12-31$3.67M(m)(m)$39.20M-$38.55M
2018-09-30$1.12M$1.07M$15.19M$33.88M-$32.74M
2018-06-30$3.68M$1.18M$13.98M$34.47M-$31.22M
2018-03-31$1.12M$967.00K$13.61M$31.10M-$30.23M
2017-12-31$999.00K(m)(m)$25.69M-$22.93M
2017-09-30$684.00K$453.00K$10.86M$18.99M-$18.19M
2017-06-30(m)(m)$7.96M$15.29M-$14.84M
2017-03-31(m)(m)$7.77M$12.93M-$12.56M
2016-12-31(m)(m)(m)$11.63M-$11.47M
2016-09-30(m)(m)$7.16M$10.81M-$10.69M
2016-06-30(m)(m)$9.84M$12.99M-$12.87M
2016-03-31(m)(m)$9.54M$13.14M-$13.04M
2015-12-31(m)(m)(m)$4.80M-$4.71M
2015-09-30$0.00(m)$9.41M$10.64M-$10.63M
2015-06-30(m)(m)$1.79M$2.60M-$2.59M
2015-03-31(m)(m)$1.74M$2.63M-$2.62M
2014-12-31(m)(m)(m)$2.60M-$2.60M
2014-09-30$0.00(m)$2.10M$2.66M-$2.66M
2014-06-30(m)(m)(m)$2.23M-$2.23M
2014-03-31(m)(m)(m)$1.04M-$1.03M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30$3.63M$613.00K$33.72M(m)-$41.33M
2025-06-30$3.23M$1.02M$23.03M(m)-$30.51M
2024-06-30$5.16M$1.43M$18.60M(m)-$27.93M
2023-06-30$4.40M$1.85M$47.86M(m)-$57.73M
2022-06-30$2.98M$2.22M$33.09M(m)-$39.32M
2021-06-30$3.60M$2.46M$15.73M(m)-$46.91M
2020-06-30$3.45M$2.66M$14.14M(m)-$27.18M
2019-06-30$2.15M$2.20M$37.16M(m)-$87.44M
2018-06-30$4.79M$2.15M$27.59M$65.57M-$61.45M
2017-06-30(m)(m)$15.74M$28.23M-$27.40M
2016-06-30(m)(m)$19.37M$26.13M-$25.91M
2015-06-30(m)(m)$3.53M$5.22M-$5.22M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2025-09-30$6.53M$1.56M$36.06M(m)-$45.13M
2024-09-30$9.51M$2.09M$24.56M(m)-$35.51M
2023-09-30$13.68M$2.70M$71.74M(m)-$86.99M
2022-09-30$22.00M$3.15M$56.74M(m)-$59.27M
2021-09-30$5.26M$3.56M$29.71M(m)-$68.06M
2020-09-30$4.90M$3.85M$20.38M(m)-$37.84M
2019-09-30$3.13M$3.03M$53.33M(m)-$142.76M
2018-09-30$4.38M$3.06M$41.48M$99.46M-$94.19M
2017-09-30$684.00K$453.00K$26.60M$47.21M-$45.59M
2016-09-30(m)(m)$26.53M$36.94M-$36.60M
2015-09-30$0.00(m)$12.94M$15.87M-$15.85M
2014-09-30$0.00(m)$4.45M$5.93M-$5.92M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$7.83M$2.09M$52.65M(m)(m)-$64.92M
2024-12-31$18.72M$2.79M$33.59M(m)(m)-$132.06M
2023-12-31$31.25M$3.42M$98.38M(m)-$367.00K-$88.48M
2022-12-31$29.75M$4.02M$77.81M(m)(m)-$86.91M
2021-12-31$6.76M$4.71M$43.81M(m)(m)-$90.86M
2020-12-31$6.48M$5.13M$29.34M(m)-$182.00K-$51.02M
2019-12-31$4.23M$4.05M$64.17M(m)(m)-$161.35M
2018-12-31$6.15M$4.33M$60.84M$138.66M(m)-$132.74M
2017-12-31$1.68M$1.21M$35.80M$72.90M-$1.83M-$68.52M
2016-12-31(m)(m)$33.48M$48.57M(m)-$48.08M
2015-12-31(m)(m)$15.34M$20.67M(m)-$20.56M
2014-12-31(m)(m)$6.51M$8.53M(m)-$8.52M
2013-12-31(m)(m)$3.49M$5.26M(m)-$5.24M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
GERON CORP (GERN)United States$0.803B-12.14
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Faeth Therapeutics, Inc. (FTH)United States$0.750B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74